Breztri is NOT Available for Adults with Asthma
Breztri (budesonide/glycopyrrolate/formoterol fumarate) is explicitly contraindicated for use in asthma and is FDA-approved only for COPD maintenance treatment. 1
FDA Labeling is Clear and Definitive
The FDA drug label for Breztri Aerosphere unequivocally states:
- Indication: Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) ONLY 1
- Limitations of Use: "Not indicated for the relief of acute bronchospasm or for the treatment of asthma" 1
- Black Box Warning: "The safety and efficacy of BREZTRI AEROSPHERE in patients with asthma have not been established. BREZTRI AEROSPHERE is not indicated for the treatment of asthma" 1
Why This Matters for Patient Safety
The FDA warning specifically addresses that LABAs (like formoterol in Breztri) used as monotherapy in asthma are associated with increased risk of asthma-related death and hospitalization 1. While Breztri contains an inhaled corticosteroid (budesonide) which mitigates some LABA risk, the triple combination including the long-acting muscarinic antagonist (LAMA) glycopyrrolate has not been studied or approved for asthma safety or efficacy 1.
What IS Available for Adults with Asthma
For adults with asthma requiring escalation beyond ICS-LABA therapy, established guidelines recommend 2, 3:
- ICS + LABA combinations (without LAMA) remain the preferred step-up therapy for moderate-to-severe persistent asthma
- Adding a LAMA to ICS-LABA can be considered, but this should be done with separate inhalers using medications specifically studied and approved for asthma (such as tiotropium)
- Recent research (2026) shows that BGF can improve lung function and reduce exacerbations in asthma 4, but this does NOT change the FDA approval status or clinical practice guidelines
Critical Clinical Pitfall
Do not prescribe Breztri for asthma patients, even if they have concurrent COPD features or smoking history. The medication lacks FDA approval for this indication, and doing so exposes patients to potential harm without established benefit-risk profile. If a patient needs triple therapy for asthma, use separate inhalers with asthma-approved medications or await formal FDA approval of triple-therapy combinations for asthma.